Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double blind study to investigate the safety and efficacy of deucravacitinib compared to methotrexate in patients with Vulvar lichen planus who have failed treatment with potent topical corticosteroids

Next Previous
Trial Profile

A randomized, double blind study to investigate the safety and efficacy of deucravacitinib compared to methotrexate in patients with Vulvar lichen planus who have failed treatment with potent topical corticosteroids

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deucravacitinib (Primary) ; Folic acid; Methotrexate
  • Indications Lichen planus; Vulval disorders
  • Focus Therapeutic Use

Most Recent Events

  • 03 Apr 2024 New trial record
  • 12 Mar 2024 Trial design published in the Trials.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top